Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over Standard Therapy in Patients with HR-positive, HER2-positive MBC By Ogkologos - February 5, 2026 354 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PATINA study Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Clinical and Biological Activity of Patritumab Deruxtecan in Patients with HR-positive,... June 5, 2023 Survival According Circulating Tumour DNA Status in the Study of Adjuvant... December 10, 2020 Adding Atezolizumab to First-Line Bevacizumab Plus Platinum Regimen Improves Survival in... December 12, 2023 Evaluation of Pemigatinib Efficacy in FGFR-Altered Advanced Solid Tumours Led to... May 17, 2024 Load more HOT NEWS This Amazing Woman Can Smell Alzheimer’s, Parkinson’s, and Cancer Years Before... Intensive care nurse describes his experience of female-centred care after breast... It Might Sound Trite But… ‘Will cancer make me infertile?’ – That Cancer Conversation
